Study outcomes
TG
SECONDARY
The median percentage difference in TG levels from the start to the end of the trial, after accounting for the placebo, was the major outcome measure (week 12). The TG baseline was determined using the mean TG value from visit 5 (week 0) as well as the value from the visit before that (one week earlier, visit 4 or visit 4.1). The mean values of TG at visits 8 (week 11) and 9 (visit 9) were used to compute the TG levels after the trial (week 12). The secondary objectives comprised median percentage changes in VLDL-C from baseline (visit 5, week 0) to the trial conclusion (visit 9, week 12). These adjustments were made to account for the placebo effects. The exploratory endpoints are low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and very low-density lipoprotein cholesterol (VLDL-TG).